论文部分内容阅读
藤沢药品工业探索研究所开发的 ARI 是醋酸喹唑啉的诱导体,是羧酸喹唑啉化合物。ARI 可分为①羧酸系统,②乙内酰脲妥因系统,③其他。在羧酸系统中开发 ARI 在日本是首次。糖尿病性合并症有神经障碍、网膜症、肾病等。原因是高血糖或血糖控制不稳定。在正常状态下由细胞膜吸收的葡萄糖97%由己糖激酶分解成乳酸。剩下的3%由醛糖还原酶(AR)代谢成山梨醇。但是,在糖尿病高血压状态下,AR 的酶活性升高,山梨醇在
ARI, developed by Fujikura Pharmaceutical Industry Research Institute, is an inducer of quinazoline acetate and is a quinazoline carboxylate compound. ARI can be divided into ① carboxylic acid system, ② hydantoin-based system, ③ other. It is the first time to develop ARI in carboxylic acid system in Japan. Diabetic complications are neurological disorders, omentum, kidney disease and so on. The reason is high blood sugar or blood glucose control instability. 97% of the glucose that is absorbed by the cell membrane under normal conditions is broken down by hexokinase to lactic acid. The remaining 3% is metabolized by aldose reductase (AR) to sorbitol. However, in hypertensive diabetic conditions, the enzyme activity of AR rises and sorbitol is present